Our drug discovery and development programs have resulted in innovative approaches by which physicians may use targeted molecular agents to more precisely treat cancer. With the limited efficacy and debilitating toxic effects of conventional cancer treatments, Introgen's low-toxicity approach to cancer treatment has drawn global interest from oncologists.
Click on the links below to find out more information about each product candidate.
- Advexin® - p53 tumor suppressor therapy
